Follow us on Twitter
This page is updated frequently with new Autoimmune Disease-related patent applications. Subscribe to the Autoimmune Disease RSS feed to automatically get the update: related Autoimmune RSS feeds. RSS updates for this page: Autoimmune Disease RSS
Autoimmune Disease patents
|| List of recent Autoimmune Disease-related patents
|Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor|
Benzoimidazol-2-yl pyrimidines, purification methods for the same, and pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritus.. .
|Kinase inhibitor and method for treatment of related diseases|
Disclosed is a compound of (aminophenylamino) pyrimidyl benzamides and a synthesis method thereof. The compound has btk-inhibition activity and can be used to treat autoimmune diseases, heteroimmune diseases, cancers or thromboembolic diseases..
|Pyridinyl and fused pyridinyl triazolone derivatives|
Or pharmaceutically acceptable salts thereof, wherein r1, r2, r3, and r4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of formula 1, to pharmaceutical compositions which contain them, and to their use for treating type i hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with btk..
|Extract and peptides derived from oryza sativa japonica group and uses thereof|
The invention relates to isolated peptides derived from oryza sativa japonica group, pharmaceutical compositions comprising same, and uses thereof for treating, preventing, ameliorating, and/or delaying the onset of inflammatory and/or neuroinflammatory and/or autoimmune diseases or conditions and in particular multiple sclerosis. The invention further relates to extracts from oryza sativa japonica group and use thereof as a dietary supplement or in a pharmaceutical composition for treating, preventing, ameliorating, and/or delaying the onset of inflammatory, and/or inflammatory, neuroinflammatory and/or autoimmune diseases or conditions.
|Determining responsiveness of autoimmune patients to dmard treatment|
The invention is directed to a method of screening patients suffering from an autoimmune disease for responsiveness to treatment with a disease modifying anti-rheumatic drug, or dmard. In some embodiments the method of the invention comprises the steps of (a) measuring an igh clonotype profile from b-cells in a sample of tissue affected by the autoimmune disease, the igh clonotype profile including igh clonotypes, igg clonotypes, and igd clonotypes; and (b) classifying a patient as being more likely to respond to dmard treatment, whenever the patient has, with respect to reference levels characteristic of normal tissue, elevated igh concentration, elevated igg fraction, and reduced igd fraction..
|Methods of treating autoimmune diseases with dll4 antagonists|
The present invention provides methods of treating a disease or disorder, in which increasing the number of regulatory t cell (treg) is beneficial, by administering to a subject suffering from such a disease or disorder a therapeutically effective amount of dll4 antagonists that block dll4-notch signal pathways, thereby increasing the number of treg. Diseases or disorders treatable by the methods of the invention include autoimmune diseases or disorders, such as multiple sclerosis (ms), diabetes, and the like.
|Anti-tnf-anti-il-17 bispecific antibodies|
Bispecific antibodies are provided that specifically bind both tumor necrosis factor alpha (tnfα) and interleukin-17 (il-17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases, including rheumatoid arthritis (ra), psoriatic arthritis (psa), and ankylosing spondylitis (as)..
|Compositions and methods for autoimmune disease|
Methods and compositions are described for categorizing and treating autoimmune disease, using single cell network profiling (scnp), where activation levels of one or more activatable elements are determined in single cells, with or without modulation, to categorize or determine treatment for the autoimmune disease.. .
|Compositions and methods for treatment of autoimmune and other disease|
Provided are methods relating to the use of cdp-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are cdp-therapeutic agent conjugates, particles comprising cdp-therapeutic agent conjugates, and compositions comprising cdp-therapeutic agent conjugates..
|Generation of immunosuppressive myeloid cells using pge2|
Therapies effective for the treatment and prevention of autoimmune diseases, chronic inflammatory diseases, transplant rejection or graft versus host disease (gvh), using prostaglandin (pg), alternative agonists of pg receptors, ep2 or ep4, or other activators of adenylate cyclase/camp/pka/creb signaling pathway are disclosed herein. These methods include the administration of a therapeutically effective amount of myeloid cells pre-treated ex vivo with the above-mentioned factors, or the in vivo administration of such agents in combination with the factors attracting myeloid precursor cells, such as myeloid cell-attracting chemokines or their inducers.
|Tumor selective chemokine modulation|
Therapies effective for the treatment and prevention of cancer and other diseases are disclosed. These methods include the administration of therapeutically effective amounts of agents that increase the local production of effector cell-attracting chemokines within tumor lesions, with concomitant suppression of local production of undesirable chemokines that attract regulatory t(reg) cells.
|Methods of treating disease with random copolymers|
The invention relates to novel methods and kits for treating or preventing disease through the administration of random copolymers. The invention also relates to the treatment of autoimmune diseases, such as multiple sclerosis, and to the administration of random copolymers in treatment regimen comprising formulations that are administered at intervals greater than 24 hours, or to sustained release formulations which administer the copolymer over a period greater than 24 hours.
|Inhibitors of c-fms kinase|
Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
|Inhibitors of bruton's tyrosine kinase|
Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
|Method of enhancing health of a person|
A method of enhancing health of a person includes administering stable water clusters to persons having an autoimmune disease, pain, a chronic disease, a mental disease, a genetic disease from malfunction of a normal dna, being an athlete for improving his performance and alleviating soreness, suffering from overworking, stress and toxins etc., by drinking a solution containing stable water clusters, swallowing small objects which contain the stable water clusters, putting a topical cream which contains the stable water clusters on skin, breathing the stable water clusters through mouth, putting drops which contain the stable water clusters into eyes, ears or nose, cleaning colon with solution that contains the stable water clusters, eating food that contains the stable water clusters, injecting solution that contain the stable water clusters into blood vessel etc.. .
|Pd-l1 based immunotherapy|
The present invention relates to the field of prophylaxis and therapy of clinical conditions including cancer, autoimmune diseases and infectious diseases. In particular there is provided vaccine compositions comprising pd-l1 or peptide fragments thereof that are capable of eliciting immune responses useful in treatment of cancer, autoimmune diseases or infectious diseases..
|Methods related to tim 3, a th1-specific cell surface molecule, for activating antigen presenting cells|
The present invention provides compositions and methods useful for promoting or reducing t-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (apc) activation.
|Modified proteases that inhibit complement activation|
Provided are methods for and compounds for modulating the complement system. In particular, compounds are provided that inhibit complement activation and compounds are provided that promote complement activation.
|St6gal i mediated modulation of hematopoiesis|
Provided are methods for reducing haematocytes in an individual. The method involve administering to an individual a composition that contains recombinant a2,6-sialyltransferase (st6gal i).
|Mutant ctla4 gene transfected t cell and composition including same for anticancer immunotherapy|
A transformed t-cell for t-cell therapy, and a composition including the same for anticancer immunotherapy. More particularly, the transformed t-cell is characterized by the transfection of a gene for coding a chimera protein.
|(z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability|
The invention relates to solid pharmaceutical compositions comprising (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide, as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from autoimmune diseases in particular systemic lupus erythematosus or chronic graft-versus-host disease, multiple sclerosis or rheumatoid arthritis.. .
|Compositions and methods for regulation of tumor necrosis factor-alpha|
The present invention relates to compositions and methods relating to an interleukin 18-inducible cytokine termed tumor necrosis factor-alpha inducing factor (taif) or interleukin-32 (il-32). In particular, the present invention provides compositions and methods for treating autoimmune diseases and cancer, in part by regulation of tumor necrosis factor-alpha expression..
And/or a salt thereof; wherein r is —oh or —op(o)(oh)2. Also disclosed are methods of using such compounds as selective agonists for g protein-coupled receptor s1p1, and pharmaceutical compositions comprising such compounds.
|Monitoring health and disease status using clonotype profiles|
There is a need or improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using dna sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions.
|Method of treating inflammation using human immunosuppressive protein|
A method of treating inflammation by administering a therapeutically effective amount of a human immunosuppressant protein (hisp) to a subject is presented. The inventors have discovered a novel immunosuppressive protein purified from the supernatant of hnt cell culture.
|Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells|
A method of preferentially delivering an active agent to an immune cell, such as a myeloid progenitor cell, a dendritic cell, a monocyte, a macrophage or a t-lymphocyte, or other cell type restricted to a functional organ system or an anatomic entity, of a mammalian subject by administering a lipid-drug complex to the subject. The lipid-drug complex is comprised of an active agent, such as a drug, and an outer surface with a targeting ligand that binds a marker on the surface of the immune cell or other cell type that is infected with or susceptible to infection with an infectious agent.
|Substituted benzoazepines as toll-like receptor modulators|
Provided are compositions and methods useful for modulation of signaling through the toll-like receptors tlr7 and/or tlr8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease..
|Methods of promoting immune tolerance|
Compositions including a polynucleotide combined with a vehicle and methods of their use to induce a suppressive immune response are provided. In some embodiments the compositions induce an increase in expression of indoleamine 2,3 dioxygenase (ido) enzyme activity in cells.
|Nkp46-mediated nk cell tuning|
The present invention relates to compounds (e.g. Antibodies) that specifically bind and inhibit nkp46.
|Commensal bacteria as signal mediators within a mammalian host|
Genetically engineered cells and microorganisms are provided for preventing or ameliorating diseases through genetically engineered quorum signaling. Therapeutic methods for using the cells and microorganisms to prevent or ameliorate diseases are also provided.
|Chimeric and humanized anti-histone antibodies|
The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein.
Compounds of formula i: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which r1, r2, r3, r4, r5, r6, x1 and x2 have the meanings given in the specification, are inhibitors of one or more jak kinases and are useful in the treatment of autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.. .
|Methods and compositions for preventing and treating a disease related to glycan dysregulation|
Contemplated compositions and methods are directed to prevent and/or treat various autoimmune diseases that are typically associated with glycan dysregulation, and especially autoimmune demyelinating diseases. Further especially contemplated aspects include animal models and systems for screening compounds to treat and/or prevent such diseases..
|Composition and method for treating an autoimmune disease|
A combination of antibiotics including rifabutin, clarithromycin and clofazimine for the treatment of an autoimmune disease such as multiple sclerosis and related diseases. In a further aspect, there is provided a composition comprising a combination of two or more antibiotic agents for the treatment of an autoimmune disease, said two or more antibiotic agents selected from rifabutin, clofazimine, and at least one macrolide..
|Genotoxicity as a biomarker for inflammation|
The invention provides a method for detection of inflammatory disease in a subject that comprises assaying a test sample of peripheral blood from the subject for a marker of dna damage. An elevated amount of marker present in the test sample compared to control sample is indicative of inflammatory disease activity, including sub-clinical inflammation.
|Multi-specific binding molecules targeting aberrant cells|
Described are proteinaceous molecules comprising at least two, preferably three to six, binding domains that bind specifically to at least two different binding sites on aberrant cells. These multi-domain and multi-specific binding molecules are preferably used in selectively modulating biological processes.
|Humanized anti-hla-dr antibodies|
The present invention concerns compositions and methods of use of humanized anti-hla-dr antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing cdc or adcc.
|Compositions and methods useful for treating diseases|
The present invention relates to a compositions for and methods of cancer treatment in which compounds of formula i or formula ii. In some aspects, the treatment of b-cell lymphoma or other hematopoietic cancers is encompassed.
|Fused amino pyridine as hsp90 inhibitors|
The present invention relates to hsp90 inhibitors containing fused amino pyridine core that are useful as inhibitors of hsp90 and their use in the treatment of hsp90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.. .
|Therapeutic agent for autoimmune diseases comprising pd-1 agonist|
Provided is a prophylactic, symptom progress-suppressive, and/or therapeutic agent for an autoimmune disease. The agent lowers the risk of infections and reduces the burden of administration to patients.
|Levels of bcma protein expression on b cells and use in diagnostic methods|
The present invention provides a method of measuring the levels of bcma in a biological sample, specifically upon the b cell surface. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as sle, and for methods for treating an individual clinically diagnosed with an autoimmune disease.
|Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders|
The present invention relates to a fusion proteins comprising regulatory t cell protein, vista (v-domain immunoglobulin suppressor of t cell activation (pd-l3) and an immunoglobulin protein (ig), preferably also containing a flexible linker intervening the vista and ig fc polypeptide. The invention also provides the use of vista polypeptides, multimeric vista polypeptides, vista-conjugates (e.g., vista-ig), and vista antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions, especially lupus, multiple sclerosis, psoriasis, psoriatic arthritis, multiple sclerosis, crohn's disease, inflammatory bowel disease and type 1 or type 2 diabetes..
|Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer|
Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (p2pdox) with antibodies or antigen-binding fragments thereof (adcs), with targetable construct peptides or with other targeting molecules that are capable of delivering the p2pdox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the adc or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-pdox) is released intracellularly.
|Soluble protein cd5 or cd6 for the treatment of cancer or tumor or for use as an adjuvant|
The present invention discloses soluble isoforms of cd5 and cd6, which are scavenger-like lymphocyte receptors, for use in the prophylaxis or therapy of disorders or in therapeutic interventions, which would benefit from an exacerbated immune response to either endogenous or exogenous antigens, resulting from a decrease in lymphocyte subpopulations with regulatory functions and/or increase in lymphocyte subpopulations with effector functions. Special disorders are cell growth disorders, and chronic infections of bacterial, viral, fungal or parasitic origin.
Popular terms: [SEARCH]
Autoimmune Disease topics: Autoimmune Disease, Immune Disease, Autoimmune, Autoimmune Diseases, Immune Diseases, Transplant, Infectious Disease, Infectious, Inflammatory Disease, Antagonist, Rheumatoid Arthritis, Proliferative, Nucleotide, Antibodies, Infectious Diseases
Follow us on Twitter
This listing is a sample listing of patent applications related to Autoimmune Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.